Triglyceride has also been shown to contribute to foam cell formation, particularly in the setting of elevated plasma VLDL and free fatty acids (FA), a profile typical of the metabolic syndrome and diabetes.13 An adverse effect of nonsteroidal LXR agonists, including T0901317, is increased triglyceride accumulation, induced by transactivation of genes involved in FA synthesis, including sterol regulatory element–binding protein (SREBP)-1c and fatty acid synthase (FASN). Here, FASN is linked to metabolic syndrome.